354 related articles for article (PubMed ID: 23463003)
1. Aldara activates TLR7-independent immune defence.
Walter A; Schäfer M; Cecconi V; Matter C; Urosevic-Maiwald M; Belloni B; Schönewolf N; Dummer R; Bloch W; Werner S; Beer HD; Knuth A; van den Broek M
Nat Commun; 2013; 4():1560. PubMed ID: 23463003
[TBL] [Abstract][Full Text] [Related]
2. [New perspective in immunotherapy: local imiquimod treatment].
Kemény L; Nagy N
Orv Hetil; 2010 May; 151(19):774-83. PubMed ID: 20427260
[TBL] [Abstract][Full Text] [Related]
3. Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream.
Torres A; Storey L; Anders M; Miller RL; Bulbulian BJ; Jin J; Raghavan S; Lee J; Slade HB; Birmachu W
J Transl Med; 2007 Jan; 5():7. PubMed ID: 17257431
[TBL] [Abstract][Full Text] [Related]
4. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.
Wenzel J; Uerlich M; Haller O; Bieber T; Tueting T
J Cutan Pathol; 2005 Apr; 32(4):257-62. PubMed ID: 15769273
[TBL] [Abstract][Full Text] [Related]
5. Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors.
Xiong Z; Ohlfest JR
J Immunother; 2011 Apr; 34(3):264-9. PubMed ID: 21389872
[TBL] [Abstract][Full Text] [Related]
6. Imiquimod and lymphatic field clearance: a new hypothesis based on a remote immune action on skin cancer.
Akkilic-Materna M; Massone C; Komericki P
Acta Derm Venereol; 2011 Jun; 91(4):432-5. PubMed ID: 21547348
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of keratinocyte proliferation by phospholipid-conjugates of a TLR7 ligand in a Myc-induced hyperplastic actinic keratosis model in the absence of systemic side effects.
Crain B; Yao S; Keophilaone V; Promessi V; Kang M; Barberis A; Maj R; Mura E; Passini N; Holldack J; Ochoa R; Cottam HB; Carson DA; Hayashi T
Eur J Dermatol; 2013; 23(5):618-28. PubMed ID: 24225049
[TBL] [Abstract][Full Text] [Related]
8. Beyond a decade of 5% imiquimod topical therapy.
A Gaspari A; Tyring SK; Rosen T
J Drugs Dermatol; 2009 May; 8(5):467-74. PubMed ID: 19537370
[TBL] [Abstract][Full Text] [Related]
9. Imiquimod in dermatology: an overview.
Hanna E; Abadi R; Abbas O
Int J Dermatol; 2016 Aug; 55(8):831-44. PubMed ID: 27387373
[TBL] [Abstract][Full Text] [Related]
10. Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions.
Wagstaff AJ; Perry CM
Drugs; 2007; 67(15):2187-210. PubMed ID: 17927284
[TBL] [Abstract][Full Text] [Related]
11. Viral and nonviral uses of imiquimod: a review.
Gupta AK; Cherman AM; Tyring SK
J Cutan Med Surg; 2004; 8(5):338-52. PubMed ID: 15868314
[TBL] [Abstract][Full Text] [Related]
12. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463.
Imbertson LM; Beaurline JM; Couture AM; Gibson SJ; Smith RM; Miller RL; Reiter MJ; Wagner TL; Tomai MA
J Invest Dermatol; 1998 May; 110(5):734-9. PubMed ID: 9579537
[TBL] [Abstract][Full Text] [Related]
13. [Eruptive epidermoid cysts during topical imiquimod treatment].
Dillies AS; Gras-Champel V; Fraitag-Spinner S; Al Saïf F; Carmi E
Ann Dermatol Venereol; 2017 Mar; 144(3):212-215. PubMed ID: 27765414
[TBL] [Abstract][Full Text] [Related]
14. Gene expression in actinic keratoses: pharmacological modulation by imiquimod.
Lysa B; Tartler U; Wolf R; Arenberger P; Benninghoff B; Ruzicka T; Hengge UR; Walz M
Br J Dermatol; 2004 Dec; 151(6):1150-9. PubMed ID: 15606509
[TBL] [Abstract][Full Text] [Related]
15. Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8+ T-cell cross-priming.
Fehres CM; Bruijns SC; van Beelen AJ; Kalay H; Ambrosini M; Hooijberg E; Unger WW; de Gruijl TD; van Kooyk Y
Eur J Immunol; 2014 Aug; 44(8):2415-24. PubMed ID: 24825342
[TBL] [Abstract][Full Text] [Related]
16. Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-alpha?
Urosevic M; Oberholzer PA; Maier T; Hafner J; Laine E; Slade H; Benninghoff B; Burg G; Dummer R
Clin Cancer Res; 2004 Aug; 10(15):4959-70. PubMed ID: 15297396
[TBL] [Abstract][Full Text] [Related]
17. Imiquimod 5% cream (Aldara) in the treatment of basal cell carcinoma.
Sapijaszko MJ
Skin Therapy Lett; 2005; 10(6):2-5. PubMed ID: 16292452
[TBL] [Abstract][Full Text] [Related]
18. TLRs to cytokines: mechanistic insights from the imiquimod mouse model of psoriasis.
Flutter B; Nestle FO
Eur J Immunol; 2013 Dec; 43(12):3138-46. PubMed ID: 24254490
[TBL] [Abstract][Full Text] [Related]
19. Imiquimod attenuates the growth of UVB-induced SCC in mice through Th1/Th17 cells.
Yokogawa M; Takaishi M; Nakajima K; Kamijima R; Digiovanni J; Sano S
Mol Carcinog; 2013 Oct; 52(10):760-9. PubMed ID: 22431065
[TBL] [Abstract][Full Text] [Related]
20. Transcutaneous immunization with a novel imiquimod nanoemulsion induces superior T cell responses and virus protection.
Lopez PA; Denny M; Hartmann AK; Alflen A; Probst HC; von Stebut E; Tenzer S; Schild H; Stassen M; Langguth P; Radsak MP
J Dermatol Sci; 2017 Sep; 87(3):252-259. PubMed ID: 28655469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
